ArticlePLoS pathogens2019
Staphylococcus aureus adhesion in endovascular infections is controlled by the ArlRS-MgrA signaling cascade.
Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 60 citations in OpenAlex.
- Methicillin-resistant Staphylococcus aureus.Nature reviews. Disease primers · 2026Review
- Collagen binding adhesin restricts Staphylococcus aureus skin infection.Nature communications · 2026Article
- Network analysis of antimicrobial resistance inNAR genomics and bioinformatics · 2025Article
- Activation of themBio · 2025Article
- Potential Compounds as Inhibitors of Staphylococcal Virulence Factors Involved in the Development of Thrombosis.Toxins · 2025Review
- Deciphering the Complex Relationships Between the Hemostasis System and Infective Endocarditis.Journal of clinical medicine · 2025Review
- The endothelium at the interface between tissues andClinical microbiology reviews · 2025Review
- Article
- Polymicrobial interactions betweenbioRxiv : the preprint server for biology · 2024Article
- The Functional Study of Response Regulator ArlR Mutants in Staphylococcus Aureus.Applied biochemistry and biotechnology · 2024Article
- Differential expression of small RNAs in biofilm-producing clinical methicillin-susceptibleHeliyon · 2024Article
- Elucidating the potential of isorhapontigenin in targeting the MgrA regulatory network: a paradigm shift for attenuating MRSA virulence.Antimicrobial agents and chemotherapy · 2024Article
- Article
- Vasculature-on-a-chip technologies as platforms for advanced studies of bacterial infections.Biomicrofluidics · 2024Review
- Thwarting resistance: MgrA inhibition with methylophiopogonanone a unveils a new battlefront against S. aureus.NPJ biofilms and microbiomes · 2024Article
- TheMicroorganisms · 2024Article
- Epitranscriptional m6A modification of rRNA negatively impacts translation and host colonization in Staphylococcus aureus.PLoS pathogens · 2024Article
- Protective Effect of Ticagrelor Against Infective Endocarditis Induced by VirulentJACC. Basic to translational science · 2023Article
- The biofilm community resurfaces: new findings and post-pandemic progress.Journal of bacteriology · 2023Review
- The Small Protein ScrA Influences Staphylococcus aureus Virulence-Related Processes via the SaeRS System.Microbiology spectrum · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
Staphylococcus aureus is a leading cause of endovascular infections. This bacterial pathogen uses a diverse array of surface adhesins to clump in blood and adhere to vessel walls, leading to endothelial damage, development of intravascular vegetations and secondary infectious foci, and overall disease progression. In this work, we describe a novel strategy used by S. aureus to control adhesion and clumping through activity of the ArlRS two-component regulatory system, and its downstream effector MgrA. Utilizing a combination of in vitro cellular assays, and single-cell atomic force microscopy, we demonstrated that inactivation of this ArlRS-MgrA cascade inhibits S. aureus adhesion to a vast array of relevant host molecules (fibrinogen, fibronectin, von Willebrand factor, collagen), its clumping with fibrinogen, and its attachment to human endothelial cells and vascular structures. This impact on S. aureus adhesion was apparent in low shear environments, and in physiological levels of shear stress, as well as in vivo in mouse models. These effects were likely mediated by the de-repression of giant surface proteins Ebh, SraP, and SasG, caused by inactivation of the ArlRS-MgrA cascade. In our in vitro assays, these giant proteins collectively shielded the function of other surface adhesins and impaired their binding to cognate ligands. Finally, we demonstrated that the ArlRS-MgrA regulatory cascade is a druggable target through the identification of a small-molecule inhibitor of ArlRS signaling. Our findings suggest a novel approach for the pharmacological treatment and prevention of S. aureus endovascular infections through targeting the ArlRS-MgrA regulatory system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.